Claret Capital Partners

Galway, Ireland – – September 14, 2026 -- Neurent Medical has secured a €25 million growth debt financing facility from Claret Capital Partners to accelerate commercial expansion of its NEUROMARK® System for chronic rhinitis treatment.

Debt facility follows €62.5 million Series C round completed earlier in 2026

The new €25 million facility builds on Neurent Medical's €62.5 million Series C financing round, which closed earlier this year. The combined capital reinforces the company's position in minimally invasive treatments for chronic inflammatory sinonasal diseases.

SHERIDAN, WYOMING - April 14, 2026 - Claret Capital Partners, a London-headquartered independent growth debt fund manager, has surpassed 200 portfolio companies and deployed more than €1.2 billion in growth capital since its 2013 founding, with deal activity accelerating sharply across the first quarter of 2026. The 200th-company milestone was reached with an investment in SIS Medical in January 2026, marking a tangible threshold for a firm that has built its franchise on non-dilutive debt instruments for expansion-stage SMEs. Operating across technology, life sciences, and climate tech, Claret targets revenue-generating businesses seeking capital without proportional equity dilution-a proposition that has gained institutional traction as venture equity markets have remained selective for growth-stage companies.